Movember

IT’S MUSTACHE SEASON.

Celebrate Movember with precise prostate cancer treatments

ACCURAY DELIVERS CLINICAL ADVANTAGES, PATIENT-FOCUSED BENEFITS

You can’t treat prostate cancer with a one-size-fits all solution. It’s not just that every patient is unique – the prostate itself can move unpredictably throughout the course of treatment due to normal patient bodily functions such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure. Accuray’s innovations give clinicians an unmatched ability to deliver highly precise and efficient treatments that correct for prostate motion in real time – minimizing side effects, improving quality of life and getting patients back to their everyday lives sooner.

Prostate Cancer Webinars

Prostate SBRT and the Pace-B Trial

Alison Tree, Consultant Clinical Oncologist MBBS, BSc, FRCR, M.D.(Res) | Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London

Watch Webinar

Intensity-Modulated Fractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings from an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial

Nicholas van As, M.D. | Royal Marsden Hospital, London, UK

Watch Webinar

SBRT as a Salvage Option for Localized Recurrent Prostate Cancer

Donald Fuller, M.D. | Genesis Healthcare Partners, San Diego, CA, USA

Watch Webinar

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction

Michael Repka M.D. | Medstar Georgetown University Hospital, Washington, DC (Currently at NYU Langone Health, New York, NY, USA

Watch Webinar

Safe and Effective Stereotactic Body Radiation Therapy (SBRT) for High-Risk Prostate Cancer Patients: 4-year Outcomes of a Phase II Trial

Victor Macias Hernandez, M.D., Ph.D. | Salamanca University Hospital, Valladolid University Hospital, Spain

Watch Webinar

The CyberKnife® System

The CyberKnife System is commonly used to treat low- to intermediate-risk prostate cancer and is the only radiotherapy device supported by years of published clinical follow-up with a large number of patients.

These studies provide reassurance to patients and providers that excellent clinical results are reproducible at any CyberKnife center

A CyberKnife® Patient Story

Dr. Robert Meier and CyberKnife® patient Mike “Bing” Crosby take to the air to discuss CyberKnife System treatments for low- to intermediate-risk prostate cancer.

Real-World Clinical Support

Listen to the medical team at the Geisinger Cancer Care about their experience with the CyberKnife S7 System.

The TomoTherapy® and Radixact® Systems

An ideal clinical solution for routine and complex prostate cancer treatments.

Treating Prostate Cancer with the Radixact System and Synchrony®

Read how Synchrony enables personalized real-time adaptive delivery of radiation treatment with the Radixact System to targets while they are in motion by synchronizing the delivery beam position to the target location precisely and accurately during continuous delivery of a treatment fraction.

Download Brochure

Treating Prostate Cancer with the TomoTherapy® System

Dr. Nadia Di Muzio of the OSR – San Raffaele Scientific Institute, Milan, Italy discusses the use of helical IG-IMRT to treat prostate cancer patients.

Watch Video

Explore Additional Clinical Evidence

Learn More